Diamyd Medical pauses start of Phase III trial – Update
The potential contamination is not connected to the new manufacturing facility being established in Umeå. Diamyd Medical has today decided to pause the start of the precision medicine Phase III trial DIAGNODE-3 as well as the initiation of other clinical trials with the diabetes vaccine Diamyd[®] (GAD/alum) pending additional evaluations of the manufacturing process. A new analysis has shown the potential presence of a contamination early in the manufacturing process of the drug substance (GAD65) used in the existing study drug. Diamyd Medical will evalaute its specific removal before